Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tanvex BioPharmaTPE:6541 -4.83%41 Days Payable is 17.78 as of Mar. 2026, which is 60% below its 10-year median of 44.66. GuruFocus rates TPE:6541 with a GF Score™ of 41/100. The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Tanvex BioPharma ranks worse than 92.88% on this metric.
The historical rank and industry rank for Tanvex BioPharma's Days Payable or its related term are showing as below:
TPE:6541'
s Days Payable Range Over the Past 10 Years
Min: 13.85 Med: 44.66 Max: 44.66
Current: 13.85
During the past 13 years, Tanvex BioPharma's highest Days Payable was 44.66. The lowest was 13.85. And the median was 44.66.
TPE:6541's Days Payable is ranked worse than 92.88% of 702
companies
in the Biotechnology industry
Industry Median: 110.85
vs TPE:6541: 13.85
Tanvex BioPharma's Days Payable
increased
from Mar. 2025 (7.86) to Mar. 2026 (17.78).
It may suggest that Tanvex BioPharmadelayed paying its suppliers.
The historical data trend for Tanvex BioPharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tanvex BioPharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Days Payable of 17.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tanvex BioPharma and its competitors. This is 60% below median its historical median of 44.66. Over the past decade, Tanvex BioPharma's Days Payable has ranged from 13.85 to 44.66. According to the industry distribution chart, Tanvex BioPharma ranks #652 out of 702 companies in the Biotechnology industry, placing it in the top 92.9%.
Is Tanvex BioPharma's Days Payable too high?
Tanvex BioPharma's current Days Payable of 17.78 is 60% below median its 10-year median of 44.66. Over the past 10 years, this metric has ranged from a low of 13.85 to a high of 44.66. The Biotechnology industry median Days Payable is 110.85. Tanvex BioPharma's value of 17.78 is 84% below this industry median. Based on the distribution chart, Tanvex BioPharma ranks #652 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tanvex BioPharma has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #652 out of 702 companies for Days Payable. This places Tanvex BioPharma in the lower half of its industry. The industry median Days Payable is 110.85. Tanvex BioPharma's value of 17.78 is 84% below this benchmark. Historically, Tanvex BioPharma's own Days Payable has ranged from 13.85 to 44.66 over the past decade. While the company's 10-year median is 44.66 vs. the industry median of 110.85, Tanvex BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current Days Payable of 17.78 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current Days Payable is 17.78, which is 60% below median its own 10-year median of 44.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Days Payable of 17.78. The current Days Payable is 17.78, which is 60% below median its 10-year median of 44.66 and 84% below the Biotechnology industry median of 110.85. Tanvex BioPharma's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Days Payable is 17.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
41GF Score
Get the complete analysis for TPE:6541
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
